Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?

Why serotonin medications may yet help children with autism
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.

How to evaluate new medications for autism
Explore more from The Transmitter
Quantifying funding sources across neuroscience labs
We want to hear from you about the sources of funding for your research.

Quantifying funding sources across neuroscience labs
We want to hear from you about the sources of funding for your research.
What kinds of support do early-career researchers need?
Help The Transmitter and Neuromatch bolster the next generation of neuroscientists.

What kinds of support do early-career researchers need?
Help The Transmitter and Neuromatch bolster the next generation of neuroscientists.
Alzheimer’s scientist forced to retract paper during his own replication effort
Gary Dunbar, a neuroscientist at Central Michigan University, was attempting to redo the 2020 paper after a collaborator admitted to using flawed data in the original work.

Alzheimer’s scientist forced to retract paper during his own replication effort
Gary Dunbar, a neuroscientist at Central Michigan University, was attempting to redo the 2020 paper after a collaborator admitted to using flawed data in the original work.